Skip to main content

Table 2 Associations between autoantibody changes and disease activity

From: Detection of autoantibodies in a point-of-care rheumatology setting

Disease/condition

Autoantibody

Change

Clinical prediction

Systemic lupus erythematosus

Anti-dsDNA

⇑

Active flare [15–17]

Anti-dsDNA

⇓

Active flare [18]

Anti-nucleosome

⇑

Active disease/lupus nephritis [19–21]

Anti-C1q

⇑

Lupus nephritis [22–24]/active disease [25]

Anti-NMDA-R

⇑

Permanent CNS impairment [26, 27]

Anti-NMDA-R

⇓

Transient CNS symptoms [26, 27]

Anti-CRP

⇑

Lupus nephritis/response to therapy [28]

Anti-interferon-α

⇓

Inactive disease [29]

Systemic vasculitis

Anti-PR3

⇑

Active disease/disease relapse [30–32]

Anti-MPO

⇑

Active disease/disease relapse [33, 34]

Anti-GBM

⇑

Active disease/disease relapse [35, 36]

Scleroderma

Anti-topoisomerase I

⇑

Active scleroderma [37–39]

Rheumatoid arthritis

Anti-drug (adalimumab)

⇑

Treatment failure [40]

Antiphospholipid syndrome/SLE

Anti-phospholipid

⇑

Procoagulant state, thrombosis [41–43]

Necrotizing myopathy

Anti-signal recognition particle

⇑

Decreased muscle strength, increased creatine kinase activity [44]

Thrombotic thrombocytopenic purpura

Anti-ADAMTS13 antibodies

⇑

Disease relapse [45, 46]

Pregnancy in SLE

Anti-Ro(SSA)/anti-Ro52

⇑

Congenital heart block [47, 48]

Anti-La(SSB)

⇑

Neonatal lupus [49]

Autoantibody serum screening

Anti-DFS70

⇑

ANA-positive healthy individuals [50, 51]